The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Seed Amplification Assay Innovation Program, 2025Quantitative SAAs for Alpha-synuclein from Various Matrices
Study Rationale: Currently existing seed amplification assays (SAAs) in which pathological protein clumps from patient samples are amplified such that they can be more easily detected for the...
-
T2T Validation - NOD2, 2025Using Knowledge Graphs to Predict NOD2 Directionality for Therapeutic Effect in Parkinson’s Disease
Study Rationale: NOD2 is a key component of our immune defense system that detects invading pathogens and promotes their removal. Under healthy, ideal circumstances, NOD2 activity has a ‘Goldilocks...
-
Research Grant, 2025Personalized Parkinson Project (PPP)
Study Rationale: We present an unbiased method for biomarker development by analyzing multiple clinical, genomic, molecular, and imaging biomarkers at four time points: baseline, 1-year, 2-year, and...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Allosteric Small Molecule Therapies for Treating GBA1-PD
Study Rationale: Some people with Parkinson’s disease (PD) have a change, or mutation, in a gene called GBA1. This gene makes an important enzyme called GCase, which helps keep brain cells healthy...
-
Research Grant, 2025Identifying Longitudinal Measures of Parkinson’s Disease Progression Using Structured and Unstructured Electronic Health Record Data
Study Rationale: In the absence of new or emerging therapies, there is strong interest in repurposing medications for treatment of Parkinson’s Disease (PD) progression if promising signals can be...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Isoform Specific Suppression of dIRE-SNCA with an ASO
Study Rationale: Alpha-synuclein (SNCA) aggregation is a hallmark of Parkinson’s disease (PD). Rare SNCA genetic duplications and triplications cause early-onset PD, suggesting a link between SNCA...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.